Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Mary M. Heckler"'
Autor:
Mary M. Heckler, Eric Glasgow, Shailaja D. Divekar, Deanna M. Tiek, Subreen A. Khatib, Rebecca B. Riggins, Colin J. Trepicchio, Jann N. Sarkaria
Publikováno v:
FASEB J
Glioblastoma (GBM; grade 4 glioma) is a highly aggressive and incurable tumor. GBM has recently been characterized as highly dependent on alternative splicing, a critical driver of tumor heterogeneity and plasticity. Estrogen-related receptor β (ERR
Autor:
Mary M. Heckler, Rebecca B. Riggins, Aykut Üren, Susette C. Mueller, Shailaja D. Divekar, Aileen I. Fernandez, Rabindra Roy, Jordan Woodrick, Tizita Zewde Zeleke, Deanna M. Tiek, Alexander Farzanegan
Publikováno v:
Oncotarget
Breast cancer remains a leading cause of cancer-related death in women, and triple negative breast cancer (TNBC) lacks clinically actionable therapeutic targets. Death in mitosis is a tumor suppressive mechanism that occurs in cancer cells experienci
Autor:
Catherine S. Grasso, Rebecca B. Riggins, Akanksha Mahajan, Hillary Stires, Joseph A. Lewis, Xiaoyong Fu, Luciane R. Cavalli, Uwe Klimach, Zhao Li, Mary M. Heckler, Balázs Győrffy, Alan Zwart, Michael J. Quist
Publikováno v:
Molecular and cellular endocrinology. 471
Invasive lobular breast cancer (ILC) is an understudied malignancy with distinct clinical, pathological, and molecular features that distinguish it from the more common invasive ductal carcinoma (IDC). Mounting evidence suggests that estrogen recepto
Autor:
Paul Sirajuddin, Muhammad Umer Choudhry, Erika Parasido, Angiela Sivakumar, Lymor Ringer, Venkata Mahidhar Yenugonda, Iman Abdelgawad, Maria Laura Avantaggiati, Olga Rodriguez, Bhaskar Kallakury, Richard T. Lee, Adam S. Feldman, Chris Albanese, John H. Lynch, Sarah Waye, Mary M. Heckler, Anatoly Dritschilo, Richard G. Pestell, Aisha Naeem, Xuefeng Liu, Lucas Tricoli, Richard Schlegel, Chin-Lee Wu
Publikováno v:
Oncotarget
// Lymor Ringer 1,* , Paul Sirajuddin 1,* , Lucas Tricoli 1,* , Sarah Waye 1 , Muhammad Umer Choudhry 1 , Erika Parasido 1 , Angiela Sivakumar 1 , Mary Heckler 1 , Aisha Naeem 1 , Iman Abdelgawad 1,6 , Xuefeng Liu 2 , Adam S. Feldman 3 , Richard J. L
Selective estrogen receptor modulators such as tamoxifen (TAM) significantly improve breast cancer-specific survival for women with estrogen receptor-positive (ER+) disease. However, resistance to TAM remains a major clinical problem. The resistant p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efc16ad067b86963c197c84e3916f7ef
https://europepmc.org/articles/PMC4079056/
https://europepmc.org/articles/PMC4079056/
Autor:
Lymor Ringer, Chris Albanese, Jeffrey A. Toretsky, Aykut Üren, Olga Rodriguez, Milton L. Brown, Tobey J. MacDonald, Frank A. Suprynowicz, Anup K. Ghosh, Yichien Lee, Mary M. Heckler, Paul Sirajuddin, Venkata Mahidhar Yenugonda, Robert I. Glazer, Richard Schlegel
Medulloblastoma is the most prevalent of childhood brain malignancies, constituting 25% of childhood brain tumors. Craniospinal radiotherapy is a standard of care, followed by a 12mo regimen of multi-agent chemotherapy. For children less than 3 y of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90a7305b20b8b2d800ee8ca5a19ddfc2
https://europepmc.org/articles/PMC3367670/
https://europepmc.org/articles/PMC3367670/
Publikováno v:
Cancer Research. 73:3322-3322
The TP53 gene is the most commonly mutated gene in all cancers, with over 50% of human cancers harboring an inactivating mutation. Most frequently when p53 is mutated, the mutation occurs as a single nucleotide substitution within the DNA-binding dom
Autor:
Yuriy Gusev, Yue Wang, Mary M. Heckler, Rebecca B. Riggins, Subha Madhavan, Cara C. Schafer, Ye Tian, Salendra Singh, Hemang Thakor
Publikováno v:
Cancer Research. 73:3570-3570
Selective estrogen receptor modulators (SERMs) such as Tamoxifen (TAM) can significantly improve breast cancer-specific survival for women with ER-positive (ER+) disease. However, resistance to TAM remains a major clinical problem. Estrogen-related r
Publikováno v:
Cancer Research. 71:LB-29
Estrogen receptor alpha-positive (ER+) breast tumors comprise ∼70% of annually diagnosed breast cancers in the United States. While pro-tumorigenic ER signaling can be blocked by endocrine therapies that either inhibit the receptor directly (Tamoxi
Autor:
Ringer L; Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Sirajuddin P; Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Tricoli L; Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Waye S; Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Choudhry MU; Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Parasido E; Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Sivakumar A; Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Heckler M; Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Naeem A; Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Abdelgawad I; Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. National Cancer Institute of Egypt, Cairo, Egypt., Liu X; Department of Pathology, Georgetown University Medical Center, Washington, DC, USA., Feldman AS; Massachusetts General Hospital, Boston, USA., Lee RJ; Massachusetts General Hospital, Boston, USA., Wu CL; Massachusetts General Hospital, Boston, USA., Yenugonda V; Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Kallakury B; Department of Pathology, Georgetown University Medical Center, Washington, DC, USA., Dritschilo A; Georgetown University Hospital, Washington, DC, USA., Lynch J; Georgetown University Hospital, Washington, DC, USA., Schlegel R; Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. Department of Pathology, Georgetown University Medical Center, Washington, DC, USA., Rodriguez O; Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Pestell RG; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Avantaggiati ML; Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Albanese C; Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. Department of Pathology, Georgetown University Medical Center, Washington, DC, USA.
Publikováno v:
Oncotarget [Oncotarget] 2014 Nov 15; Vol. 5 (21), pp. 10678-91.